Trophic Effects of Skeletal Muscle Extracts on Ventral Spinal Cord Neurons In Vitro: Separation of a Protein with Morphologic Activity from Proteins with Cholinergic Activity

R. G. SMITH,* J. McMANAMAN,† AND S. H. APPEL‡
Departments of *Biochemistry and †Neurology, Baylor College of Medicine, Houston, Texas 77030

ABSTRACT Protein factors derived from skeletal muscle separately promote neurite elongation and acetylcholine synthesis in cultured rat ventral spinal neurons. Morphologic factor activity (neurite-inducing activity) is specifically found in rat skeletal muscle and cord neuron extracts, decreases with the postnatal age of the rats from which muscle extract is prepared, and increases in rat hindlimb muscle after 5 d of denervation. Cholinergic factor activity (acetylcholine synthesis–stimulating activity) is found in extracts of rat cerebral cortex and cardiac muscle in addition to spinal cord and skeletal muscle, increases with animal age, and decreases following 5 d of denervation. Biochemically, the factors responsible for these activities differ in their liability to denaturing conditions, apparent molecular weights, isoelectric points, and lectin-binding specificities. Under reducing conditions, morphologic activity is isolated in a single acidic glycoprotein with an M, of 35,000, while acetylcholine synthesis–stimulating activity is found in multiple species of different molecular weights. Thus, acetylcholine synthesis–promoting activities and neurite growth–promoting activity appear to reside in different molecules. Significant purification of several of these factors has been achieved.

Skeletal muscle, the target organ for motoneurons, influences the survival, growth, and differentiation of its innervating neurons. In avian and mammalian embryos, procedures which reduce or block muscle function in vivo subsequently prevent the death of many motoneurons (53), delay the reduction of polyneuronal connections (3, 42), and induce motoneuron neurite sprouting (10). Electrical stimulation of such denervated skeletal muscle blocks this terminal sprouting in neurons (7) and increases the rate of loss of polyneuronal innervation (47). These developmental effects have been attributed to skeletal muscle–derived neurotrophic factors acting in a retrograde fashion on motoneurons (24, 54).

The main evidence for the existence of such diffusible neurotrophic factors comes from in vitro experimentation. Media conditioned on cultured myotubes and skeletal muscle homogenates have been shown to augment motoneuron survival (2, 57, 61), general neuron phenotypic appearance including neurite elongation (15, 27, 60), and motoneuron neurotransmitter induction (20, 21, 60). However, since these muscle-derived activities have not been substantially purified, it is not clear whether a single factor possesses both morphologic and cholinergic properties, or whether multiple factors are involved. In vitro experiments with embryonic parasympathetic (45) ganglia suggest that several agents can separately influence different aspects of neuron development. Molecular sieving has been used to separate the ciliary neuron morphologic- and cholinergic-enhancing activities (45).

In vivo experiments with spinal cord also suggest differential regulation of motoneuron development. In rat and chick, the critical periods for motoneuron survival (13, 25, 35), loss of polyneuronal connections (6), and cholinergic differentiation (30, 52) occur at different developmental stages. Process density and hyperinnervation in surviving motoneurons are greatest at the stage of motoneuron death (24), while subsequent postnatal loss of polyneuronal innervation is not accompanied by additional loss of motoneurons (35, 49). Further...
We have previously demonstrated that skeletal muscle extract increases both neurite outgrowth and acetylcholine (ACh) synthesis in cultures of dissociated embryonic rat ventral spinal cord (60). In the present paper, we provide evidence suggesting that the effects of muscle extract on neurite outgrowth and ACH synthesis in vitro are differentially regulated, and that the molecules possessing morphologic- and cholinergic-enhancing properties have distinctly different physical properties which can be readily separated by several biochemical techniques. Furthermore, we report the partial purification of a morphologic-enhancing factor which has no cholinergic-stimulating activity, and several cholinergic-enhancing factors without apparent morphologic-enhancing activity (58, 59).

MATERIALS AND METHODS

Tissue culture media were purchased from Gibco Laboratories (Grand Island, NY). Horse serum was obtained from Kansas City Biologicals Inc. (Kansas City, MO), and was heat inactivated at 50°C for 45 min before addition to media. Muscle extracts used were of analytical grade. Radiochemicals were purchased from New England Nuclear (Boston, MA), except for [3H]choline chloride, which was obtained from Amersham Corp. (Arlington Heights, IL). All purification steps were performed on ice or in a cold room set to 4°C.

Cell Culture: Neuronal cultures were prepared from the dissociated, arachnoid-free ventral spinal cords of 13-14-d embryonic rats (Zivic-Miller, Allison Park, PA). Spinal cords were first separated longitudinally into dorsal and ventral portions. Ventral cord portions were then pooled, exposed to a 0.08% trypsin solution at 37°C for 15 min, and dissociated by gentle trituration through a fire-polished pasteur pipette. The dissociated cells were plated onto polylysine-coated Falcon tissue culture dishes (Falcon Labware, Becton, Dickinson & Co., Oxnard, CA). For morphologic assays, cells were plated at a density of 520 cells/mm² on 35-mm culture dishes. For assays of ACH synthesis and accumulation, cells were either treated as above, or plated at a fivefold higher density (2,500 cells/mm²) onto 24-well multiwell plates. Cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% horse serum, 2 mM glutamine, 33 mM glucose, and 0.15 mM Garamycin. One day after plating, cytosine arabinoside (5 x 10⁻⁵ M) was added to this medium to prevent cell proliferation. After 6 h before death, iodinated a-BTX (41) was injected into all rat hindlimbs.

To determine the yield of these biological activities from muscle extracts, a biological activity unit was defined. One unit is that amount of sample required to produce a 50% stimulation over a 50% stimulation over a 50% control over control levels, either in cell process density, or in ACh synthesis. Activity levels could be determined from activity/concentration curves for each sample, and quantitated by the best linear or logarithmic curve fit of the resultant concentration analysis data (r² > 0.9).

To test extract samples for denaturation by pH, protease, nuclease, heat, and reducing agents, concentrations corresponding to initial half-maximal biological activity were used to plot the rate of change in factor activity. Unless otherwise described in the text, only just-saturating concentration data has been presented.

ACh Synthesis: De novo ACh synthesis and accumulation was measured after 6 d in culture by a modification of Johnson and Pilar's assay (29). Cultures were depolarized for 10 min in a Tyrode's buffer with 25 mM KCl (to deplete existing stores of ACh), and then incubated in normal Tyrode's solution containing 10 μM [³H]choline chloride (2-4 Ci/mmol, Amersham Corp.) for 30 min. The cultures were washed with PBS three times to remove unused radioactive substrate, and extracted with 15:85 1 N formate/acetone, containing [³H]-labeled tetrathylammonium bromide as an internal standard (New England Nuclear). These formic acid/acetone extracts were transferred to glass test tubes and dried by vacuum centrifugation. The contents of each tube were then resuspended in 2 ml of HEPES-buffered Tyrode's solution, pH 7.2, without potassium, and an aliquot was taken for measurement of choline uptake. Samples were centrifuged for 20 min at 2,500 g, and the supernatant (containing the choline and ACh) was collected and split into two equal fractions. One fraction from each well was treated with 0.02 U acetylcholinesterase (Boehringer-Mannheim Biochemicals, Mannheim, FRG) at 37°C for 10 min. Free choline was phosphorylated by adding 0.02 U of choline kinase (Sigma Chemical Co., St. Louis, MO), 10 mM ATP, 10 mM MgCl₂, and 10 M Moll solution (final pH in solution was 8.2). The ACh was separated from phosphorylated choline by extraction in tetraphenylboron/acetoni trile (19), and carried into a toluene scintillant upper phase, which was removed for counting. The amount of ACH synthesis and accumulation was determined by first correcting for the loss of internal standard, and then taking the difference between the esterase-treated and untreated fractions as the amount of [³H]ACh in each well. [³H]ACh synthesis and accumulation was normalized to cell concentration by analysis of the DNA content in each culture well, and was expressed as the number of picomoles of [³H]ACh/μg DNA per hour.

Morphometric Assay: Cultured cells were examined for process outgrowth by phase-contrast microscopy. As an indicator of average process density, the ratio of processes per cell (p/c ratio) was measured 3-4 d after extract addition. This ratio was obtained by counting the number of processes with lengths greater than one cell diameter in random microscopic fields, and dividing by the total number of cells in each field. Cell counts were checked by plate DNA analysis, and cell viability at the time of counting was periodically tested by trypan blue exclusion. Twenty to sixty microscopic fields, representing between 1-3% of the total dish surface area, were counted for each plate. Process lengths in these fields were also measured, using a radiuclide. Periodically, process length and density measurements were photographically verified.

Rat Denervation: 6-wk-old Sprague-Dawley rats were denervated under ether anesthesia by cutting off the sciatic nerve at the level of the greater trochanter, or by injecting 2 μg/hindlimb per day of α-bungarotoxin (α-BTX) (Miami Serpentarium Laboratories, Miami, FL) every day. Completeness of denervation was tested each day by assessment of resistance to forced hindlimb flexion and by loss of reflex hindlimb extension. These rats were fed ad libitum. The results were verified at the time of muscle harvest by measurement of denervation-dependent increases in plasma acetylcholinesterase activity (to deplete existing stores of ACh), and then incubated in normal Tyrode's solution containing 10 μM [³H]choline chloride (2-4 Ci/mmol, Amersham Corp.) for 30 min. The cultures were washed with PBS three times to remove unused radioactive substrate, and extracted with 15:85 1 N formate/acetone, containing [³H]-labeled tetrathylammonium bromide as an internal standard (New England Nuclear). These formic acid/acetone extracts were transferred to glass test tubes and dried by vacuum centrifugation. The contents of each tube were then resuspended in 2 ml of HEPES-buffered Tyrode's solution, pH 7.2, without potassium, and an aliquot was taken for measurement of choline uptake. Samples were centrifuged for 20 min at 2,500 g, and the supernatant (containing the choline and ACh) was collected and split into two equal fractions. One fraction from each well was treated with 0.02 U acetylcholinesterase (Boehringer-Mannheim Biochemicals, Mannheim, FRG) at 37°C for 10 min. Free choline was phosphorylated by adding 0.02 U of choline kinase (Sigma Chemical Co., St. Louis, MO), 10 mM ATP, 10 mM MgCl₂, and 10 M Moll solution (final pH in solution was 8.2). The ACh was separated from phosphorylated choline by extraction in tetraphenylboron/acetoni trile (19), and carried into a toluene scintillant upper phase, which was removed for counting. The amount of ACH synthesis and accumulation was determined by first correcting for the loss of internal standard, and then taking the difference between the esterase-treated and untreated fractions as the amount of [³H]ACh in each well. [³H]ACh synthesis and accumulation was normalized to cell concentration by analysis of the DNA content in each culture well, and was expressed as the number of picomoles of [³H]ACh/μg DNA per hour.
Precipitates were resuspended in 1/5 their original volume, and dialyzed for 12-16 h, through Spectropor 6 1,000 MWCO dialysis membranes and concentrated threefold by lyophilization prior to assay of biological activity.

**Precipitation by Ammonium Sulfate:** Ammonium sulfate fractionation was performed at 0°C by the dropdownwise addition of 3.9 M (NH4)2SO4, (Schwarz/Mann Div., Spring Valley, NY) to crude muscle extract. Ammonium sulfate concentration was increased in steps to complete saturation. After each step addition, extract samples were allowed to equilibrate for 1.5 h, and precipitated proteins were then pelleted by a 30-min centrifugation at 15,000 g. Precipitates were resuspended in 1/5 their original volume, and dialyzed for 12-16 h, through Spectropor 6 1,000 MWCO dialysis membranes against either PBS, or PBS plus 0.5 M NaCl. Dialyzed samples were stored at -80°C for further use, or filter sterilized for assay.

**Preparative Isoelectric Focusing (IEF):** IEF was performed at 6°C on an LKB Multiphotor 2117 apparatus. A Sephadex IEF gel slurry (Pharmacia Fine Chemicals, Uppala, Sweden), containing muscle extract 46–60% ammonium sulfate fraction mixed with pH 4-9 ampholines (Serva Fine Biochemicals Inc., Garden City Park, NY), was poured into an electrophoresis tray and focused at 8 W constant power for 16 h. At the end of the run, protein banding was determined by overlaying a strip of Whatman 1 paper (Whatman Inc., Clifton, NJ) on the edge of the gel surface. This paper print was removed, fixed in 10% trichloroacetic acid, and developed with Coomassie Blue. The gel was then separated into 30 fractions, and a small aliquot of each fraction was collected for pH determination. Protein contained in the remainder of each fraction was eluted by the method of Winter et al. (69), using alternating 0.5-ml washes of PBS and 0.5 M NaCl in PBS. Eluted proteins were dialyzed through 1,000 MWCO dialysis membranes and concentrated threefold by lyophilization prior to assay of biological activity.

**Gel Filtration Chromatography:** Gel filtration steps were performed in LKB and Pharmacia columns. Sizing column flow rates were maintained with an LKB 2132 Microperpex peristaltic pump. All column fractions were collected on Gilford Micron fractionator (Gilford Medical Electronics, Inc., Middleton, WI) fraction collectors. UV absorbance was assayed for each fraction at 280 nm on a Gilford 250 spectrophotometer (Gilford Instrument Laboratories, Inc., Oberlin, OH).

**Determination of Glycoprotein Nature, and Lectin-Affinity Chromatography:** Sodium periodate, cyanogen bromide-activated Sepharose 4B, and the lectins Ricinus communis, Lotus tetragonolobus, Concanavalin A, and Lens culinaris were obtained from Sigma Chemical Co. α-Mannosidase, β-glucosidase, neuraminidase, and Limulin were purchased from Boehringer-Mannheim Biochemicals. Glycosidases and lectins were first conjugated to cyanogen bromide-activated Sepharose 4B (51, 65), and then poured into mini econo-columns from Bio-Rad Laboratories, Richmond, CA. The specific binding activities of these lectin-coupled beads were assayed using radiolabeled sugars. After removal of radiolabeled tracer, muscle extract fractions were then added to the lectin columns. Choice of running and elution buffers depended upon the specific lectin-sugar pair (51, 65). Columns were washed in 20 vol of lectin-specific buffer, and bound molecules then eluted in 2-5 ml of buffer containing 100 mM NaCl for sialic acid specific eluting sugar. Samples were dialyzed against 1% normal PBS solution through 1,000 MWCO Spectropor 6 membranes, and concentrated fourfold by lyophilization prior to testing biological activity.

**Other Procedures:** Lactate dehydrogenase activity (45) and acetylcholinesterase activity (48) were both assayed by homogenates of spinal cord cultures either 12 h after initial cell plating, or after 5 d in vitro. Cultures were assayed in the absence or presence of 200 μg skeletal muscle extract/ml culture medium. Protein content was assayed by the technique of Lowry et al. (38) or by fluorometric assay (64). Culture DNA assays were performed according to the method of Hinegardner (28).

**RESULTS**

Under our culture conditions, 95% of added cells attached to dish substrata within 1 h of plating. When plated at a density of 300 cells/mm², 37 ± 7% of the cells remained bound to the culture dish after 6 d in vitro (4 d after removal of cytosine arabinoside). At the higher plating density of 2,500 cells/mm², apparent cell survival was 50 ± 8%. 85 ± 10% of these cells were labeled by the neuron-selective marker protein tetanus toxin.

Approximately one-fifth of the plated cells began to extend processes within 12 h of attachment. Although this process extension was influenced by plating density and by culture glial content, the addition of skeletal muscle extract independently augmented both the rate and extent of cell process outgrowth (Fig. 1). When measured 3 d after the addition of saturating concentrations of muscle extract, process density increased from 0.36 ± 0.01 processes per cell in untreated cultures, to 1.51 ± 0.05 processes per cell in extract-treated cultures. The percentage of tetanus toxin–labeled cells extending neurites also increased relative to both total tetanus toxin–labeled cells, from 20 ± 5% without treatment, to 60 ± 5% after muscle extract addition. Comparable increases in cell process length were observed, from an average of 50 ± 1 μm in controls, to 163 ± 5 μm after 3 d in extract-supplemented cultures. These effects were not due to the binding of a muscle extract component to the polylysine substratum, since a 16-h extract–substratum incubation before cell addition had no effect on neural process outgrowth, measured 3 d after plating.

Further, muscle extract addition neither altered total or tetanus toxin–labeled cell survival, as determined by cell counting and culture DNA content, nor enhanced general cell metabolism. Culture acetylcholinesterase activity increased only 15 ± 5% relative to control values after 4 d in 200 μg extract protein/ml culture medium, while extract similarly produced an insignificant 10 ± 6% increase in total lactate dehydrogenase activity compared to control cultures (even though lactate dehydrogenase activity increased in both extract and control cultures by threefold during the 4-d test period).

Changes in cell morphology occurred more rapidly than did increases in cholinergic activity. Maximal process density was achieved after 3–5 d in culture, while ACh synthesis and accumulation continued to increase in vitro for at least 3 wk. When measured 4 d after the initial addition, the rate of ACh synthesis and accumulation in these cells typically increased threefold, from 2.52 ± 0.24 pmol [3H]ACh synthesized/μg DNA per hour in control cultures, to 7.98 ± 0.34 pmol [3H]-ACh/μg DNA per hour in muscle extract–treated neurons. Factor activities, however, varied somewhat between individual extract preparations. The concentration of muscle extract required to give a half-maximal increase in ACh synthesis in spinal neuron cultures (50 μg protein/ml culture medium) was only one-fourth of that necessary for the same change in either process density (200 μg protein/ml culture medium) or process length. These findings suggest that factors regulating process density and ACh synthesis in ventral spinal cord may be different. Three biological criteria are described below providing further evidence for this hypothesis.

**Tissue Specificity**

Fig. 2 provides evidence that extracts of different newborn rat tissues differentially augment neurite outgrowth and cho-
FIGURE 1 Effect of addition (three consecutive days) of muscle extract on neurite extension in cultured ventral spinal cord cells.
Control cultures (a) were maintained in normal growth medium, while experimental cultures were further treated with 25 (b), 100 (c), or 400 (d) μg muscle extract protein/ml of culture medium. Bar, 100 μm. x 250.

FIGURE 2 Effect of different neonatal rat tissue extracts on (a) neurite density and (b) [3H]ACh synthesis and accumulation in cultured ventral cord neurons. Extracts of spleen (SP), liver (LI), lung (LU), skin (SK), kidney (KI), cerebral cortex (CC), cardiac muscle (CM), skeletal muscle (SM), or spinal cord (SC) were individually added in equal 200 μg extract protein/ml culture medium aliquots 3 d after the addition of 200 μg protein/ml extract aliquots to ventral cord cultures, only skeletal muscle and spinal cord homogenates significantly stimulated cell process outgrowth. In sister cultures, cholinergic activity was not only increased by skeletal muscle and spinal cord extracts, but also by homogenates of other tissues with dense cholinergic innervation, such as cardiac muscle and cerebral cortex. Even at higher concentrations, these latter two extracts had little effect on process outgrowth, suggesting that an increase in cholinergic activity is apparent with two tissue extracts that do not promote morphologic differentiation. Neurite outgrowth in heart and brain extracts was not actively prevented by the production of a specific inhibitory factor, because mixing just-saturating activity levels of skeletal muscle extract with activity-saturating levels of cardiac muscle extract prior to cell addition did not block process outgrowth.

Age Dependence

The cholinergic and morphologic activities of muscle extract aliquots to triplicate cultures. In each experiment, cultures were assayed 3 d later for neurite outgrowth. Additionally, triplicate sister cultures were tested after 4 d for the amount of [3H]ACh synthesized/μg DNA per hour, relative to control (CO) values. These results are the means of four experiments ± SDs. The value for mean control morphologic activity was 0.47 processes per cell with an interexperiment SD of 0.31, and an intraexperiment SD of 0.14. The ACh synthesis mean value was 2.45 pmol [3H]ACh/μg DNA per hour with an SD between experiments of 0.89, and an SD of 0.07 within an experiment.

SMITH ET AL. Separation of Rat Motoneurotrophic Factors 1611
tract also display different age dependencies. The levels of morphologically active factor obtained from muscle extracts of different aged rats decreased with the increasing age of those rats (Fig. 3). When expressed per milligram of muscle protein (Fig. 3A), there was an 80% loss in this activity during the first 3 wk after birth. Morphologic activity levels obtained from the combination of newborn and adult muscle extracts suggested that this loss was the result of a decrease in activating factor concentration rather than an increased amount of an inhibitory substance. In contrast, cholinergic-stimulating activity in older animal muscle was at least slightly greater than that found in newborn tissues. When expressed as total activity per limb, a 400% increase in cholinergic activity was observed with maturation (Fig. 3B).

Response to Denervation

To determine whether the age-dependent changes in morphologic and cholinergic factor activities could be reversed by axotomy, we examined the results of physical (sciatic nerve ligation) or chemical (repeated hindlimb injection with α-BTX) denervation of adult rat hindlimb muscle on in vitro tests of these two indices of neuron maturation. Both of these methods produced a loss of distal hindlimb function within 1 d of treatment, and a 35-fold increase in muscle extrajunctional ACh receptor levels (measured by 125I-α-BTX binding) at the time of muscle homogenization.

After denervation, the low morphologic-stimulating activity of adult muscle extract increased almost to newborn activity levels (Fig. 4). With combined physical and chemical dener-

\[ \text{FIGURE 3} \] Comparison of rat limb muscle development to muscle extract-induced changes in neurite extension and cholinergic development in vitro. Extracts of rat hindlimb muscle, obtained at ages ranging from birth to 6 wk, were added to ventral spinal cord cultures. Although multiple extract protein concentrations were tested, this figure depicts the results (for each rat age) of addition of single subsaturating 100 μg muscle extract protein/ml culture medium concentration, on process density (O), measured after 3 d, or on [3H]ACh synthesis (O), assayed 4 d after initial extract addition. For each experiment, data from triplicate cultures are expressed as a percent of newborn extract activity (100%), relative to control culture values (0%). The results are normalized per mg muscle extract protein in a, or per limb (b), and are the mean of four experiments (12 cultures per point) ± SEM. Actual mean values for process outgrowth are 0.41 ± 0.19/0.09 for control and 1.63 ± 0.30/0.17 for newborn extract–treated cultures, where interexperiment SD is expressed above interexperiment SD. Comparable mean values for cholinergic activity were 2.59 ± 0.66/0.09 pmol [3H]ACh/μg DNA per hour, and 5.62 ± 0.74/0.16 pmol [3H]ACh/μg DNA per hour for control and newborn extrac–treated cultures, respectively.

Differential Effects of Denaturation

The morphologic- and cholinergic-enhancing activities of muscle extract could be separated by their biochemical as well as biologic properties. For example, they differed with respect to their rates of heat inactivation. Although both factor activities were destroyed by heating to 60°C for 1 h, the morphologic factor lost activity more rapidly than did the cholinergic factor (Fig. 4). At 60°C, this rate of morphologic activity loss was nonlinear, and appeared to follow an exponential curve with half-maximal activity decay at 8.8 min. At just-saturating activity concentrations, the rate of loss in cholinergic activity with heating was linear, with half of its activity being lost in 29 min.

Morphologic- and cholinergic-stimulating activities also differed in their rates of inactivation by trypsin. In the presence of 0.1 mg/ml trypsin at 37°C, loss of morphologic activity followed a linear time course, with a 1/2 of inactivation observed at 48 min (Fig. 5B). Loss of cholinergic activity was nonlinear with time, however, and could be modeled by two
FIGURE 4 Denervation-induced changes in process density and cholinergic activity. Muscle extracts were prepared 5 d after distal hindlimb denervation, either by cutting the sciatic nerve (■), by daily injections of 2 µg α-BTX per limb per day (△), by a combination of these two methods (○), or after sham operation and daily saline injections (□). These extracts were added to dissociated ventral spinal cord neurons. Concentration-dependent effects of the extracts were assayed in triplicate cultures 3 d after initial addition for differences in (a) the P/C ratio or in (b) [3H]ACh synthesis, measured in triplicate sister cultures after 4 d. Results are expressed as a percent of untreated culture values, and are the mean of three experiments (9 cultures per point) ± SEM. Control mean values for morphologic and cholinergic activities were 0.63 ± 0.27/0.10 processes per cell, and 2.21 ± 0.74/0.14 pmol [3H]ACh/µg DNA per hour, respectively (mean control value + interexperiment SD/intraexperiment SD).

lines that provided an activity loss t1/21 at 16 min and a t1/22 at 23 min. This effect was blocked by pretreatment of the enzyme with 1 mg/ml soybean trypsin inhibitor. Neither extract incubation at 37°C, nor addition of soybean trypsin inhibitor to extract, had any effect on the activities induced by muscle extract.

The cholinergic and morphologic activities exhibited different sensitivities to pH (Fig. 5C). The morphologic activity was stable at acid pH, but was destroyed above pH 7.5. Conversely, cholinergic-stimulating activity was stable between pH 6 and 9, with only partial activity being lost below pH 6. Total cholinergic activity was destroyed, however, at pH greater than 9.

Both activities were stable to a 6-h incubation with either DNAase 1 or RNAase A. Further, neither activity was lost when incubated with disulfide reducing agents like 1–5 mM dithiothreitol (DTT) or 2-mercaptoethanol. In fact, when tested at subsaturating activity concentrations, a 12-h incubation with 2 mM DTT increased total cholinergic activity in muscle extract by 2.2-fold. This increased activity was preserved after subsequent incubation with 2–5 mM N-ethylmaleimide (NEM). Because DTT and NEM were dialyzed from the extract before addition to cultures, these agents did not directly affect the survival or differentiation of the cells.

Precipitation by Salts

Both morphologic- and cholinergic-stimulating activities of muscle extract could be reversibly precipitated by the step-gradient addition of ammonium sulphate. Most morphologic factor activity and cholinergic factor activity was precipitated and recovered in the 47–62% saturated ammonium sulfate fraction of muscle extract. When morphologic- and cholinergic-stimulating activities were also tested for susceptibility to denaturation at high salt concentrations, both were stable to 2 M NaCl, but were labile to treatment with 6 M guanidine hydrochloride.

Separation by Size

As a direct test for the presence of multiple neurotrophic species, the active 46–62% ammonium sulfate sample was fractionated by Sephacyr S-200 gel filtration chromatography (Fig. 6). In the presence of the reducing agents DTT and NEM, a single morphologically active species was found with an Mₐ of 33,000–37,000 (Fig. 6C). In contrast, two peaks of cholinergic activity were found, with Mₐ’s of 55,000–65,000 and 14,000–17,000 (Fig. 6D). If DTT and NEM were not added to the extract before S-200 sizing chromatography, morphologic activity eluted as several activity peaks with Mₐ’s averaging greater than 200,000, 125,000, 100,000, 67,000, and 33,000 (Fig. 6A). Omission of DTT and NEM also increased the number of cholinergic activity peaks. These species eluted with Mₐ’s of greater than 200,000, 75,000–85,000, 55,000–65,000, 40,000–45,000, and 14,000–17,000 (Fig. 6B).

Under both nonreducing and reducing conditions, morpho-
The effects of heat, trypsin, and extremes of pH on the loss of muscle extract morphologic factor activity and cholinergic factor activity. Muscle extracts were (a) heated to 60°C for 5–60 min, (b) incubated for 90 min at 37°C (T) with either soybean trypsin inhibitor (S+T+E), treated with active 0.1 mg/ml trypsin for 5–90 min, or (c) dialyzed for 6 h against different buffered solutions of pH 3–11 prior to addition to cultures. Prior to use, trypsin and soybean trypsin inhibitor (Sigma Chemical Co.), were both assayed for proteolytic activity with the protease substrates toluene-sulphonyl-l-arginine methyl ester and benzoyl-l-arginine ethyl ester. In each experiment, samples were assayed in triplicate ventral spinal cord cultures for either neurite outgrowth (○) or ACh synthesis (●). Reported results of heat and trypsin denaturation of muscle extract are the mean of three experiments (9 cultures per point) ± SEM, whereas assays of extract pH stability are the mean of two experiments (6 cultures per point) ± SEM. Control values for morphologic activity were 0.34 ± 0.02 processes/cell for a, 0.58 ± 0.23/0.09 processes for b, and 0.35 ± 0.06/0.04 for c. Control values for cholinergic activity were 2.42 ± 0.57/0.20 pmol [3H]ACh/µg DNA per hour for a, 2.13 ± 0.88/0.14 pmol [3H]ACh/µg DNA per hour for b, and 2.55 ± 1.22/0.17 pmol [3H]ACh/µg DNA per hour for c. Results refer to the mean control values ± interexperiment SD or range/intraexperiment SD. This method for normalizing biological activity provides consistent quantitative comparisons, both between preparations of muscle extract, and between experiments.

Separation by Preparative IEF

Morphologic and cholinergic activities also had different apparent isoelectric points (Fig. 7). After electrofocusing of the 46–62% extract ammonium sulfate fraction, morphologic activity was usually found to focus as a single band at pH 4.8, while the cholinergic activity focused as multiple bands at pH 9.2, 7.7, 5.2, and 4.1. On occasion, a very small amount of morphologic activity was also found at a pH range corresponding to a pl of 7.5–8.

The Mₐ's of the four cholinergically active IEF fractions were determined by gel filtration on S-200 or ACA-202 gels. Samples were pooled by pl activity peak and concentrated by lyophilization prior to addition to a sizing column. Cholinergic activity initially recovered from the basic fraction (pl = 9.2), eluted from an ACA-202 column at an Mₐ of 14,000–18,000 (Fig. 8A). The fraction corresponding to a pl of 7.7 contained an activity peak with an Mₐ of 55,000–65,000, and when chromatographed on ACA-202, also produced a second activity peak with an Mₐ of 5,000–8,000 (Fig. 8B). The pH 5.2 and 4.1 fractions contained only low molecular weight (<5,000) cholinergically active species. After S-200 sizing chromatography, the morphologically active isoelectric frac-
Recovery and fractionation of factor activities by sizing chromatography. Results are primarily derived from the column fractionation experiment depicted in Fig. 3. Morphologic-specific activity from Sephacryl S-200 columns were assessed in peak activity fractions by regression analysis of activity/concentration curves. Total activities were determined from all fractions contributing to a peak. Data are accompanied by the range for each value, as delineated from the regression curves. Average total recovery (92% before reduction and 124% after reduction and alkylation) was obtained from five different S-200 column fractionation experiments.

Additivity of Cholinergic Activities

When tested together on cultured cells, the cholinergically active ammonium sulfate fractions produced additive increases in cholinergic activity. To test whether the four cholinergic gel filtration fractions might also provide additive stimulations of ACh synthesis, active species were first partially purified by ammonium sulfate fractionation, ACA-202 gel chromatography, and preparative IEF. As previously observed (Figs. 6D and 8B), the 55,000-mol-wt factor provided a smaller maximal stimulation at saturating activity than did...
FIGURE 7 Biological activity profile from preparative IEF of a 46-62% ammonium sulfate fraction of muscle extract. Morphologic factor activity (---) and cholinergic factor activity (—) obtained from triplicate culture assays of IEF fractions, depicted as a function of the pH of each fraction. Results are the mean of three experiments (9 cultures per point) ± SEM. Mean control values for morphologic and cholinergic activity were 0.65 ± 0.18/0.03 processes/cell and 2.70 ± 1.06/0.07 pmol [3H]ACh/µg DNA per hour, where interexperiment SD is expressed above intraexperiment SD.

### TABLE II. Cholinergic Activity: 1,880 Units Added to Column

| Size       | Specific activity | Total activity |
|------------|------------------|----------------|
| mol wt     | U/mg protein     | U              |
| 250,000    | 651 ± 63         | 214 ± 20       |
| 75,000–85,000 | 86 ± 42     | 117 ± 57       |
| 55,000–65,000 | 96 ± 10     | 67 ± 7         |
| 14,000–17,000 | 4,250 ± 618 | 136 ± 26       |

Recovery and fractionation of factor activities by sizing chromatography. Results are primarily derived from the column fractionation experiment depicted in Fig. 3. Cholinergic-specific activity from Sephacryl S-200 columns were assessed in peak activity fractions by regression analysis of activity/concentration curves. Total activities were determined from all fractions contributing to a peak. The data are accompanied by the range for each value, as delineated from the regression curves. Average total recovery (32% before reduction and 21% after reduction and alkylation) was obtained from five different S-200 column fractionation experiments.

### TABLE III. Cholinergic Activity: 4,400 Units Added to Column

| Size       | Specific activity | Total activity |
|------------|------------------|----------------|
| mol wt     | U/mg protein     | U              |
| 25,000     | 145 ± 21         | 200 ± 21       |
| 14,000–17,000 | 1,000 ± 46   | 1,580 ± 88     |
| 5,000–7,000 | 400 ± 15     | 194 ± 31       |
| 2,000      | 30,000           | 1,394 ± 13     |

Recovery and fractionation of factor activities by sizing chromatography. Results are primarily derived from the column fractionation experiment depicted in Fig. 3. Cholinergic-specific activity from LKB ACA-202 columns were assessed in peak activity fractions by regression analysis of activity/concentration curves. Total activities were determined from all fractions contributing to a peak. The data are accompanied by the range for each value, as delineated from the regression curves. Average total recovery (77%) was obtained from three different ACA-202 column fractionation experiments.

Determination of Glycoprotein Nature

Both the morphologic- and cholinergic-stimulating activities of skeletal muscle extract appeared to be produced by glycoproteins. Each activity was completely destroyed by a 20-min, 37°C incubation with 5 mM sodium periodate. This effect was not the result of direct damage to cells, since periodate was removed by dialysis prior to addition to cultures. However, because periodate may have denatured muscle extract activities by some other action than the cis-diol cleavage of sugar groups, morphologic and cholinergic factor binding to lectin columns was also assessed (Table IV). Muscle extract fractions, each partially purified by ammonium sulfate fractionation, sizing chromatography, and preparative IEF, were added to lectin columns. Columns were then washed with 10-20 ml of a PBS carrier solution containing calcium, magnesium, and/or manganese ions, as needed, to stabilize any of the other three smaller species (Fig. 9A). Moreover, even though these three lower molecular weight fractions had comparable saturating activity levels, their maximal activities were significantly less than that of the crude high speed supernatant.

When the 55,000-mol-wt factor was added to any of the lower molecular weight species, the combined cholinergic activity was equal to that found in the crude homogenate (Fig. 9B). However, when the lower molecular weight factors were mixed with one another and added to cultures, no such additivity of cholinergic factor stimulation was observed.

Recovery and fractionation of factor activities by sizing chromatography. Results are primarily derived from the column fractionation experiment depicted in Fig. 3. Cholinergic-specific activity from Sephacryl S-200 columns were assessed in peak activity fractions by regression analysis of activity/concentration curves. Total activities were determined from all fractions contributing to a peak. The data are accompanied by the range for each value, as delineated from the regression curves. Average total recovery (32% before reduction and 21% after reduction and alkylation) was obtained from five different S-200 column fractionation experiments.
lectin–sugar binding. Glycoproteins were eluted with buffer containing an excess of the relevant specific lectin-binding sugars.

The 34,000–37,000-mol-wt morphologically active factor bound selectively to Lens culinaris, concanavalin A, and Lotus tetragonolobus lectins, and was eluted by a-methylmannoside (Table IV). Although these lectins all have specificity for α-mannosyl (4, 34) residues, there was no loss of morphologic factor activity when muscle extract fractions were incubated for 1 h with sepharose-linked β-glucosidase or α-mannosidase.

The cholinergically active 14,000–17,000- and 55,000–60,000-mol-wt factors did not bind to concanavalin A or Lens lectin columns, but did bind to a sialic acid–specific lectin, eluting with N-acetylneuraminic acid (Table IV). In addition, incubation of dialyzed muscle extract at 37°C with 0.1 U of sepharose-linked neuraminidase greatly reduced its ability to stimulate ACh synthesis (t_{1/2} = 7.5 min), but had no effect on morphologic factor activity. The lowest molecular weight cholinergically active species did not bind to columns specific for either of these sugar types, and was not destroyed by neuraminidase.

**Factor Purification**

We have partially purified several of the biologically active muscle extract–derived species. Beginning with ~100 ml of crude rat muscle homogenate, ammonium sulfate fractionation, sizing gel chromatography, preparative IEF, and lectin column chromatography were sequentially performed to increase the purity of some of the biologically active factors. By these methods, the morphologically active protein has been estimated to be purified ~75,000-fold with more than a 35% yield (Table V).

The analysis of purification for the 14,000–17,000- and 55,000–60,000-mol-wt cholinergic factors, however, has posed problems. This difficulty was due to both the presence of multiple cholinergically active species that contribute to the total biological activity, and to the continual problem of loss of the low molecular weight factors from less purified fractions. At present, the 55,000–60,000-mol-wt factor is more than 100-fold more active, per mg protein, than is the crude muscle homogenate. There was a 3% recovery of cholinergically active material in this molecular weight range relative to total activity (Table V). The 14,000–17,000-mol-wt factor has, by the same scheme, been purified almost 3,700-fold with a final yield of 18%.

**DISCUSSION**

Our in vitro data indicate that skeletal muscle–derived trophic activities separately enhance spinal cord neurite outgrowth and ACh synthesis. The biological evidence for this conclusion is fourfold: (a) although both morphologic- and cholinergic-enhancing activities are present in extracts of skeletal muscle and spinal cord, cholinergic-stimulating activity is also selectively found in two tissues without morphologic activity (e.g., cardiac muscle and cerebral cortex); (b) morphologic and cholinergic factor activities from muscle differ with respect to time course of action and concentration dependence; (c) morphologic-enhancing activity declines significantly as a function of age, with skeletal muscle extracts from 3-wk-old rats possessing only 20% of the activity of newborn rat skeletal muscle, whereas cholinergic-enhancing activity in muscle in-
FIGURE 9. Additivity of cholinergic factor activities. (a) Maximal levels of factor-induced ACh synthesis (depicted here by solid bars) were determined by preparation of activity/concentration curves for each of the size-separable cholinergically active factors. (b) Comparison of the maximal level of cholinergic-stimulating activity from crude muscle extract with levels obtained by adding together, at saturating concentrations, the partially purified cholinergic factor activities (indicated in the legend). Each bar represents the bioassay of triplicate cultures for each of two experiments ± SD. Control values for cholinergic activity was 2.56 ± 0.39 ± 0.24 pmol [3H]ACh/μg DNA per hour, with the range of interexperiment values expressed above the mean SD for individual experiments. Phosphate-buffered saline carrier (PBS), high speed supernatant of muscle extract (CR), and 55,000- (55), 17,000- (17), 6,000- (6), and 1,500- (1.5) mol-wt cholinergically active factors.

TABLE IV. Lectin Binding Specificity of Factor Activities

| Lectin                     | Eluting sugar            | Activity in wash   | Activity in eluate |
|----------------------------|--------------------------|--------------------|--------------------|
|                            |                          | % total added ± SD | % total added ± SD |
| A. Triticum vulgaris       | n-Acetylglucosamine      | 103 ± 12           | 8 ± 16             |
| Arachis hypogaea           | Galactose                | 104 ± 20           | 3 ± 18             |
| Lotus tetragonobolus       | L-Fucose                 | 99 ± 33            | 53 ± 32            |
| Concanavalin A             | a-Methylmannopyranoside  | 24 ± 15            | 90 ± 22            |
| Lens culinaris             | a-Methylmannopyranoside  | 27 ± 21            | 105 ± 20           |
| Limulin                   | N-Acetylneuraminic acid  | 86 ± 15            | 15 ± 20            |
| B. Lens culinaris          | a-Methylmannopyranoside  | —                  | (a)                |
| Concanavalin A             | a-Methylmannopyranoside  | 105 ± 17 (b)       | 4 ± 20             |
| Limulin                   | N-Acetylneuraminic acid  | 90 ± 15* (a)       | 12 ± 17            |
|                           |                          | 86 ± 30* (b)       | 5 ± 20             |
|                           |                          | 4 ± 6 (a)          | 98 ± 15            |
|                           |                          | 34 ± 12 (b)        | 54 ± 16            |

Binding and recovery of morphologic factor activity (A) and cholinergic factor activity (B) from various immobilized lectins. Values presented are the percentage of total activity applied to each lectin column and recovered in the buffer wash, or in the displacement sugar eluate.

* Data for (a) 55,000- and (b) 17,000-mol-wt factors.
TABLE V. Purification of Factor Activities

| Treatment | Specific activity | Purification | Total activity | Yield |
|-----------|------------------|--------------|----------------|-------|
| Morphologic (35,000 mol wt) factor activity |  |  |  |  |
| Tissue homogenate | <1 | — | — | — |
| 100,000 g supernatant* | 10 | 1 | 5,100 | 100 |
| 46-60% (NH₄)₂SO₄ fraction | 122 | 12 | 4,670 | 92 |
| S-200 sizing chromatography | 4,456 | 446 | 3,910 | 77 |
| Preparative IEF | 384,600 | 38,500 | 2,295 | 45 |
| Lectin chromatography | 747,000 | 75,000 | 1,940 | 38 |
| Cholinergic factor activity |  |  |  |  |
| Tissue homogenate | <2 | — | — | — |
| 100,000 g supernatant* | 17 | 1 | 5,500 | 100 |
| 46-60% (NH₄)₂SO₄ fraction | 190 | 11 | 5,450 | 99 |
| S-200 sizing chromatography | 1,000* (a) | 6 (a) | 200 (a) | 4 (a) |
| Preparative IEF | 935 (a) | 55 (a) | 170 (a) | 3 (a) |
| Lectin chromatography | 2,055 (a) | 123 (a) | 170 (a) | 3 (a) |

* Also referred to as crude muscle extract.
† Data for (a) 55,000- and (b) 17,000-mol-wt factors.

TABLE VI. Summary of Physical Properties for the Morphologic and Cholinergic Factor Activities of Muscle Extract

| Treatment | Morphologic activity | Cholinergic activity |
|-----------|----------------------|----------------------|
| Heat | Labile t½ = 60 ° = 9 min | Labile t½ = 29 min |
| Trypsin | Labile t½ = 37 ° = 48 min | Labile t½ = 16 min |
| pH | Stable at acidic pH | Maximal activity at pH 5-8.5 |
| DTT | Stable | Stable |
| β-Mercaptoethanol | Stable | Stable |
| NEM | Stable | Stable |
| Periodate | Labile 20 min at 37 ° | Labile 20 min at 37 ° |
| Neuraminidase | Stable | Partial loss t½ = 7.5 min |
| α-Mannosidase | Stable | Stable |
| β-Glucosidase | Stable | Stable |
| Lectin binding | Con A, Lens, Lotus | Limulin |
| Ammonium sulfate | 35-60% | 47-62% |
| DEAE-cellulose | 0.1-0.3 M NaCl | 0.70-0.95 M NaCl |
| CM-cellulose | 0.04-0.08 M NaCl | 0.25-0.40 M NaCl |
| Periodate | 0.35-0.62 M NaCl | 0.9-1.0 M NaCl |
| Sizing (post-reduction) | 33,000-35,000-mol-wt to 35,000 mol wt | 14,000-17,000 mol wt |
| | 5,000-7,000 mol wt | 1,200-1,500 mol wt |

band on one-dimensional SDS gel electrophoresis, and lesser degrees of purification for the various cholinergic factors.

Our results are consistent with in vivo experimental data, and extend previous work using co-cultured muscle (20), conditioned medium from cultured myotubes (15, 21, 27), and extracts of muscle tissue (58, 60) to stimulate spinal cord development. Further, our data complement recent work by other groups. For example, several attempts have been made to purify motoneuropotrophic factors using assays that measure only total neuron survival and cell process outgrowth. Since motoneurons comprise a small percentage of ventral spinal cord cells, though, it is possible that their survival and development are regulated differently than other cord neurons (46, 61). Thus, even though the age and denervation-dependent changes in our morphologic activity paralleled specific effects on in vivo motoneuron neurite sprouting and retraction, >60% of the neurons in the cultures increased neurite outgrowth in response to factor addition. It may not be surprising, then, that other reported molecular weights for soluble factors effecting general spinal cord (16, 27, 62), cortical neuron (33), and parasympathetic motoneuron (17) survival and process sprouting are roughly equivalent to our reported values for nonreduced morphologic factor aggregates. Under reducing conditions, our total morphologic activity was quantitatively recovered as a 35,000-mol-wt acidic glycoprotein factor. Similarly, the bovine brain factor that directs neurite outgrowth in dissociated bovine cortical neurons is also a single acidic 37,000-mol-wt glycoprotein (33).

These morphologically active, soluble proteins augment neurite growth rate (16) in a different manner than do substratum-binding proteoglycans (37), which are mechanically essential for cell substratum attachment and subsequent neurite outgrowth (11). Although a few reports (9, 36) have suggested that a substrate-binding proteoglycan complex containing laminin is the only neurite-promoting factor present in muscle-derived fractions, our morphologic factor neither bound to dish substratum nor altered serum components. It thus behaves more like a previously reported soluble substance which augments neurite outgrowth in cultures already containing the substratum-bound factor (12).

Tests of cholinergic activity are more selective of motoneuron function than are general in vitro morphologic assays. Thus, the identification of cholinergic-enhancing factors by several groups (20, 21, 32, 45, 57, 60, 68) may provide more specific insights into motoneuron development than can observation of general growth or survival agents. Yet, our separation of spinal cord neuron morphologic and cholinergic...
factors does not exclude the possible existence of a motoneu- 
rotrophic hormone which specifically enhances both moto-
neuron process outgrowth and neurotransmitter synthesis. 
In fact, the detection of such a factor has been suggested by 
muscle extract IEF. From several gels, we isolated a small 
amount of morphologic activity at a pl corresponding to that 
of the 55,000-mol-wt cholinergic-enhancing factor. This heat-
labile, neutral 55,000-mol-wt glycoprotein further appears to 
have selective effects on in vitro motoneuron development. 
When added to ventral cord neuron cultures at saturating 1- 
5 \( \mu \)g/ml concentrations, it promoted both neurite outgrowth 
and cholinergic development in choline acetyltransferase-
antibody-labeled neurons, without altering motoneuron sur-
vival, the survival and morphologic development of other 
cord neurons or non-neuronal cells, or culture protein content 
(61). Equivalently specific in its actions is the 50,000-mol-wt 
protein from iris muscle-containing eye extracts that induces 
cholinergic activity in ciliary ganglion motoneurons without 
affecting general neuron growth or non-neuronal cell division 
(45). Further, monoclonal antibodies directed against a simi-
lar 56,000-mol-wt neutrotrophic species (or a co-purifying 
antigen) have selectively prevented denervation-induced 
sprouting in motoneurons (23).

Several other reports have identified acid-extractable, heat-
stable 50,000–60,000-mol-wt proteins derived from heterol-
ogous sera or whole rat embryos, which generally act to 
promote "neurotropic" cell survival (31) and mesodermal 
cell mitogenesis (39). However, the effects of our high molec-
ular weight cholinergic factor were normally observed in the 
presence of serum-containing media, and were additive to the 
actions of horse and calf serum on choline acetyltransferase 
antibody-labeled cell growth and cholinergic activity. There-
fore, this protein is probably not such a serum-derived factor.

Our 55,000-mol-wt species was additive to each of the three 
lower molecular weight species in reconstituting the maximal 
cholinergic-enhancing activity of the unfractionated extract. 
Further, the 14,000–17,000-mol-wt glycoprotein (which has a 
pl of -9.2), had a very different effect on general cell growth 
than did the high molecular weight factor. At factor concen-
trations equal to its cholinergic-stimulating levels, the 14,000– 
17,000-mol-wt species increased culture protein synthesis, and 
induced a 2–3-fold increase in cell division when added to rat 
L6 myoblasts, 3T3 fibroblasts, and primary rat astrocytes 
(1), which augments the survival and growth of 
ciliary ganglion motoneurons without 
affecting general neuron growth or non-neuronal cell division 
(45). Further, monoclonal antibodies directed against a simi-
lar 56,000-mol-wt neutrotrophic species (or a co-purifying 
antigen) have selectively prevented denervation-induced 
sprouting in motoneurons (23).

Several other reports have identified acid-extractable, heat-
stable 50,000–60,000-mol-wt proteins derived from heterol-
ogous sera or whole rat embryos, which generally act to 
promote "neurotropic" cell survival (31) and mesodermal 
cell mitogenesis (39). However, the effects of our high molec-
ular weight cholinergic factor were normally observed in the 
presence of serum-containing media, and were additive to the 
actions of horse and calf serum on choline acetyltransferase 
antibody-labeled cell growth and cholinergic activity. There-
fore, this protein is probably not such a serum-derived factor.

Our 55,000-mol-wt species was additive to each of the three 
lower molecular weight species in reconstituting the maximal 
cholinergic-enhancing activity of the unfractionated extract. 
Further, the 14,000–17,000-mol-wt glycoprotein (which has a 
pl of -9.2), had a very different effect on general cell growth 
than did the high molecular weight factor. At factor concen-
trations equal to its cholinergic-stimulating levels, the 14,000– 
17,000-mol-wt species increased culture protein synthesis, and 
induced a 2–3-fold increase in cell division when added to rat 
L6 myoblasts, 3T3 fibroblasts, and primary rat astrocytes 
(1), which augments the survival and growth of 
ciliary ganglion motoneurons without 
affecting general neuron growth or non-neuronal cell division 
(45). Further, monoclonal antibodies directed against a simi-
lar 56,000-mol-wt neutrotrophic species (or a co-purifying 
antigen) have selectively prevented denervation-induced 
sprouting in motoneurons (23).

Several other reports have identified acid-extractable, heat-
stable 50,000–60,000-mol-wt proteins derived from heterol-
ogous sera or whole rat embryos, which generally act to 
promote "neurotropic" cell survival (31) and mesodermal 
cell mitogenesis (39). However, the effects of our high molec-
ular weight cholinergic factor were normally observed in the 
presence of serum-containing media, and were additive to the 
actions of horse and calf serum on choline acetyltransferase 
antibody-labeled cell growth and cholinergic activity. There-
fore, this protein is probably not such a serum-derived factor.

Our 55,000-mol-wt species was additive to each of the three 
lower molecular weight species in reconstituting the maximal 
cholinergic-enhancing activity of the unfractionated extract. 
Further, the 14,000–17,000-mol-wt glycoprotein (which has a 
pl of -9.2), had a very different effect on general cell growth 
than did the high molecular weight factor. At factor concen-
trations equal to its cholinergic-stimulating levels, the 14,000– 
17,000-mol-wt species increased culture protein synthesis, and 
induced a 2–3-fold increase in cell division when added to rat 
L6 myoblasts, 3T3 fibroblasts, and primary rat astrocytes 
(1), which augments the survival and growth of 
ciliary ganglion motoneurons without 
affecting general neuron growth or non-neuronal cell division 
(45). Further, monoclonal antibodies directed against a simi-
lar 56,000-mol-wt neutrotrophic species (or a co-purifying 
antigen) have selectively prevented denervation-induced 
sprouting in motoneurons (23).
Boenziger, J. U., and D. Fiete. 1979. Structural determinants of concanavalin A: specificity for oligosaccharides. J. Biol. Chem. 254:2400-2407.

Brown, M. C. 1984. Sprouting of motor nerves in adult mice: a recapitulation of development. Trends Neurosci. 7:10-14.

Brown, M. C., J. K. S. Jensen, and D. Van Essen. 1976. Polynuronal innervation of skeletal muscle in the new-born rats and its elimination during maturation. J. Physiol. (Lond.) 270:299-310.

Brown, M. C., L. H. Naulet, P. N. Bullock, B. K. Schrier, and P. G. Nelson. 1977. The intraneuronal transport of acetylcholine and cholinergic enzymes in rat sciatic nerve during regeneration after various types of axonal trauma. J. Neurosci. 15:260-166.

Brown, M. C., R. L. Holland, and R. Ironson. 1980. Nodal and terminal sprouting from motor nerves in fast and slow muscles of the mouse. J. Physiol. (Lond.). 306:493-510.

Buller, A. M. 1975. Choline acetyltransferase and acetylcholinesterase in the developing rat spinal cord. Exp. Neurol. 47:172-180.

Calófi, A. L., and L. F. Reichardt. 1984. Motorneurons purified by cell sorting respond to two distinct activities in myoblast conditioned medium. Dev. BioL 106:194-210.

Carbonetto, S., and K. J. Muller. 1982. Nerve fiber growth and the cellular response to axotomy. Curr. Top. Dev. Biol. 17:33-71.

Coffin, P. M. 1978. Induction of neurite outgrowth by a conditioned medium factor bound to the culture substratum. Proc. Natl. Acad. Sci. USA. 75:5210-5213.

Coffin, P. M., and A. Dawson. 1982. Conditioned medium increases the role of neurite elongation: separation of this activity from the substratum-bound inducer of neurite outgrowth. J. Neurosci. 2:1005-1010.

Chu-Wang, J.-W., and R. W. Oppenheim. 1978. Cell death of motoneurones in the chick embryo spinal cord. II. Quantitative and qualitative analysis of degeneration in the ventral cord, including evidence for axon outgrowth and limb innervation prior to cell death. J. Neurosci. 8:489-491.

Dicker, P., P. Holmgren, P. Pettiean, and E. Rozengurt. 1981. Similiarities between fibroblast-derived growth factor and platelet-derived growth factor. Exp. Cell Res. 140:103-107.

Doblin, B. L., and J. N. Barrett. 1980. Conditioned medium enhances neurite outgrowth from rat spinal cord explants. Dev. BioL 74:184-195.

Doblin, B. L., and J. N. Barrett. 1983. Characterization of neurite outgrowth-promoting activity of conditioned medium on spinal cord explants. Dev. Brain Res. 4:433-441.

Ehresmann, T., M. Belys, E. O. Jacobson, and J. Porath. 1979. Neurite outgrowth elicited by embryonic chick heart: partial purification of active factor. Nervous L. 145:91-95.

Elisman, G., K. Courtney, V. Andris, and R. M. Feasterhorne. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 8:788-791.

Ellman, G., K. Courtney, V. Andres, and R. M. Feasterhorne. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 8:788-791.

Ellman, G., K. Courtney, V. Andres, and R. M. Feasterhorne. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 8:788-791.

Ellman, G., K. Courtney, V. Andres, and R. M. Feasterhorne. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 8:788-791.

Ellman, G., K. Courtney, V. Andres, and R. M. Feasterhorne. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 8:788-791.

Ellman, G., K. Courtney, V. Andres, and R. M. Feasterhorne. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 8:788-791.

Ellman, G., K. Courtney, V. Andres, and R. M. Feasterhorne. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 8:788-791.

Ellman, G., K. Courtney, V. Andres, and R. M. Feasterhorne. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 8:788-791.

Ellman, G., K. Courtney, V. Andres, and R. M. Feasterhorne. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 8:788-791.

Ellman, G., K. Courtney, V. Andres, and R. M. Feasterhorne. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 8:788-791.

Ellman, G., K. Courtney, V. Andres, and R. M. Feasterhorne. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 8:788-791.

Ellman, G., K. Courtney, V. Andres, and R. M. Feasterhorne. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 8:788-791.

Ellman, G., K. Courtney, V. Andres, and R. M. Feasterhorne. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 8:788-791.

Ellman, G., K. Courtney, V. Andres, and R. M. Feasterhorne. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 8:788-791.

Ellman, G., K. Courtney, V. Andres, and R. M. Feasterhorne. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 8:788-791.

Ellman, G., K. Courtney, V. Andres, and R. M. Feasterhorne. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 8:788-791.

Ellman, G., K. Courtney, V. Andres, and R. M. Feasterhorne. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 8:788-791.

Ellman, G., K. Courtney, V. Andres, and R. M. Feasterhorne. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 8:788-791.

Ellman, G., K. Courtney, V. Andres, and R. M. Feasterhorne. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 8:788-791.

Ellman, G., K. Courtney, V. Andres, and R. M. Feasterhorne. 1961. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 8:788-791.